Omeros

Omeros

Yahoo Finance • 5 hours ago

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER

NEW YORK, July 14, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Omeros Corporation (“Omeros” or the “Company”) (NASDAQ: OMER).  Such investors are advised to contact Danielle Peyton at newactio... Full story

Yahoo Finance • 6 hours ago

Noteworthy Tuesday Option Activity: DINO, ZS, OMER

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in HF Sinclair Corp (Symbol: DINO), where a total of 31,865 contracts have traded so far, representing approximately 3.2 million unde... Full story

Yahoo Finance • yesterday

Omeros Corporation Investigated by the Portnoy Law Firm

LOS ANGELES, July 13, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Omeros Corporation, (“Omeros" or the "Company") (NASDAQ: OMER) investors that the firm has initiated an investigation into possible securities fraud, and may fil... Full story

Yahoo Finance • 7 days ago

OMER Investors Have Opportunity to Join Omeros Corporation Fraud Investigation with the Schall Law Firm

LOS ANGELES, July 08, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Omeros Corporation (“Omeros” or “the Company”) (NASDAQ... Full story

Yahoo Finance • 8 days ago

Is Omeros Corporation (OMER) the Best Get Rich Quick Stock to Buy Right Now?

Omeros Corporation (NASDAQ:OMER) is among the best get rich quick stocks to buy right now. On June 26, Brandon Folkes from H.C. Wainwright trimmed the price target on Omeros Corporation (NASDAQ:OMER) to $33 from $40 and reaffirmed a Buy ra... Full story

Yahoo Finance • 18 days ago

Acadia rises as EU backs Rett syndrome therapy

[Diagnosis Rett syndrome and tablets on a wooden table.] designer491 Acadia Pharmaceuticals (ACAD [https://seekingalpha.com/symbol/ACAD]) added ~13% on Friday after an expert panel of the EU drug regulator, the European Medicines Agency,... Full story

Yahoo Finance • 22 days ago

NovoCure vs. Omeros: Which Emerging Pharmaceutical Stock Is a Better Buy in 2026?

Deciding between NovoCure (NASDAQ:NVCR) and Omeros (NASDAQ:OMER) requires a look at two different stages of medical innovation. Both companies aim to solve difficult health challenges using unique scientific approaches. NovoCure is establ... Full story

Yahoo Finance • 24 days ago

Intellia Therapeutics vs. Omeros: Which Emerging Biotech Stock Is a Better Buy in 2026?

Choosing between Intellia Therapeutics (NASDAQ:NTLA) and Omeros (NASDAQ:OMER) in 2026 requires balancing the explosive potential of gene editing against the steady rollout of newly approved orphan disease treatments. Intellia Therapeutics... Full story

Yahoo Finance • 3 months ago

Omeros Corp (OMER) Q4 2025 Earnings Call Highlights: A Turnaround with Strategic Deals and FDA ...

This article first appeared on GuruFocus. Net Income (Q4 2025): $86.5 million or $1.22 per share. Net Loss (Q3 2025): $30.9 million or $0.47 per share. Net Gain from Zaltnibart Transaction: $237.6 million. Non-GAAP Adjusted Net Income (Q4... Full story

Yahoo Finance • 3 months ago

Omeros Non-GAAP EPS of $3.14 beats by $2.78

* Omeros press release [https://seekingalpha.com/pr/20458005-omeros-corporation-reports-fourth-quarter-and-year-end-2025-financial-results] (OMER [https://seekingalpha.com/symbol/OMER]): Q4 Non-GAAP EPS of $3.14 beats by $2.78. * At De... Full story

Yahoo Finance • 3 months ago

Omeros Corporation Reports Fourth Quarter and Year-End 2025 Financial Results

– Conference Call Today at 4:30 p.m. ET SEATTLE, March 31, 2026--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the fourth quarter and year ended Dece... Full story

Yahoo Finance • 3 months ago

After-Hours Earnings Report for March 31, 2026 : NKE, PVH, RH, NCNO, OMER, PLAY, BYND, DUOT, REKR, DGXX, BHST, SPWH

The following companies are expected to report earnings after hours on 03/31/2026. Visit our Earnings Calendar for a full list of expected earnings releases. Nike, Inc. (NKE)is reporting for the quarter ending February 28, 2026. The sh... Full story

Yahoo Finance • 4 months ago

Earnings week ahead: NKE, TLRY, SPCE, BYND, NNDM, CAG, and more

[Nest of Eggs] LindaJoHeilman As the calendar turns from March to April, a holiday-shortened week still delivers a diverse set of earnings with the potential to offer fresh directional cues. Consumer and brand momentum will be in focus w... Full story

Yahoo Finance • 6 months ago

Omeros Gets FDA Approval for YARTEMLEA as First Therapy for TA-TMA

Omeros Corporation OMER recently announced that the FDA approved its YARTEMLEA (narsoplimab-wuug) to treat hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA), a frequent life-threatening condition that can oc... Full story

Yahoo Finance • 7 months ago

FDA Approves Omeros' Yartemlea, First Approved Drug For Rare Post-Transplant TA-TMA

(RTTNews) - Omeros Corp. (OMER) said Thursday that the U.S. Food and Drug Administration has approved Yartemlea (narsoplimab-wuug) for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA), a ra... Full story

Yahoo Finance • 7 months ago

Wednesday Sector Leaders: Drugs, Biotechnology Stocks

In trading on Wednesday, drugs shares were relative leaders, up on the day by about 1.6%. Leading the group were shares of Omeros, up about 84.5% and shares of Dynavax Technologies up about 38.6% on the day. Also showing relative strengt... Full story

Yahoo Finance • 7 months ago

Sector Update: Health Care Stocks Rise Wednesday Afternoon

Health care stocks were rising in recent early Wednesday afternoon trading, with the NYSE Health Car PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 7 months ago

OMER Surges 81% On FDA Approval Of Yartemlea For Transplant-Related TA-TMA

(RTTNews) - Omeros Corporation (OMER) jumped 81.14%, closing at $15.85, up $7.10, after the U.S. FDA approved Yartemlea (narsoplimab-wuug) for the treatment of transplant-associated thrombotic microangiopathy (TA-TMA), a serious complicati... Full story

Yahoo Finance • 7 months ago

Omeros Corporation (OMER): Novo Nordisk Deal Creating Buzz

Omeros Corporation (NASDAQ:OMER) is one of the Best Micro-Cap Stocks to Invest in According to Analysts.Omeros Corporation (OMER): Novo Nordisk Deal Creating Buzz Latest reports show that Omeros Corporation (NASDAQ:OMER) has closed a deal... Full story

Yahoo Finance • 7 months ago

Do You Believe Omeros Corporation’s (OMER) New Monoclonal Antibody Has Strong Chances of Approval?

Jacob Fund is a mutual fund company, released its third-quarter 2025 investor letter. A copy of the letter can be downloaded here. The latest quarter showed continued market recovery, with major equity indexes reaching new all-time highs.... Full story